AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02552862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
Study NCT04215432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gel containing propolis extract, nanovitamin C and nanovitamin E
Description: The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.
Study NCT04215432 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
Study NCT01877889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
Study NCT01877889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
Study NCT04295863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Standard
Description: For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
Study NCT04295863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Standard
Description: For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
Study NCT04295863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Extended
Description: For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
Study NCT04295863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Extended
Description: For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
Study NCT04689971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline
Study NCT04689971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline
Study NCT04689971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B combination
Description: Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
Study NCT02246608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWT Standard of Care plus Oasis wound product
Description: Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
Study NCT02246608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine NPWT Standard of Care
Description: Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
Study NCT02174744 — intervention group
Intervention type: OTHER
Intervention: numeric pain rating scale
Study NCT02454153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REMStar Positive Airway Pressure
Description: Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
Study NCT02454153 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LifeStyle Counseling
Description: Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
Study NCT00478309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Study NCT00478309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study NCT00794066 — intervention group
Intervention type: PROCEDURE
Intervention: measuring the ankle brachial index
Description: Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de).
Study NCT00800410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) services
Description: CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
Study NCT01651091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation Awareness Training
Description: Psychotherapy Intervention
Study NCT01651091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study NCT02062203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 (therapeutic dose)
Description: Single oral dose of AKB-6548 at a therapeutic dose level
Study NCT02062203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 (supratherapeutic dose)
Description: Single oral dose of AKB-6548 at a supratherapeutic dose level
Study NCT02062203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of placebo
Study NCT02062203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose of 400 mg moxifloxacin
Study NCT01332292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
Study NCT01704703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Panitumumab 6,0 mg/kg day 1 i.v. 60 min
Study NCT02039674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV on Day 1 of each 3-week cycle
Study NCT02039674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
Study NCT02039674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Orally tablet once daily
Study NCT02039674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Oral tablet once daily
Study NCT01278485 — intervention group
Intervention type: DRUG
Intervention: Sulphonylurea
Description: SU administered according to usual practice.
Study NCT01704703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
Study NCT01278485 — intervention group
Intervention type: DRUG
Intervention: Metformn
Description: Metformin administered according to usual practice.
Study NCT02561637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Study NCT02561637 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Study NCT04097093 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Intravenous (IV), 0 mg, Day One Only, One Day
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
Study NCT00469560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study NCT02692781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-6031
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
Study NCT02692781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control
Study NCT01015066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
Study NCT01015066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Oral tables, 50 mg/d, once a day for six months
Study NCT01069146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia induction
Description: Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
Study NCT00166088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
Study NCT00166088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Dietary Supplement
Description: The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
Study NCT02084147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET
Study NCT02084147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo CT
Study NCT02084147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI
Study NCT04142554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
Study NCT04212260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercises
Description: Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
Study NCT04212260 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
Study NCT01682902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
Study NCT04665583 — intervention group
Intervention type: OTHER
Intervention: Prehabilitation
Description: Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
Study NCT01682902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
Study NCT02910076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 MG Plaquenil three times a day
Study NCT04689295 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise programme 1
Description: Schroth three dimensional scoliosis therapy method
Study NCT00377832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 975 mg
Description: Acetaminophen 975 mg by mouth once only
Study NCT01959373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroencephalograms (EEG)
Study NCT01959373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electro-myography (EMG)
Study NCT02272257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Direct Access Physical Therapy
Description: Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
Study NCT02272257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician management
Description: Physician management including advice, medication, and referral to physical therapy or other provider.
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Intravenous (IV), 600 mg, Day One Only, One Day
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Intravenous (IV), 300 mg, Day One Only, One Day
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Intravenous (IV), 150 mg, Day One Only, One Day
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
Study NCT02543762 — intervention group
Intervention type: PROCEDURE
Intervention: Chromoendoscopy
Description: Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
Study NCT03713632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab 300mg every 2 or every 4 weeks
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
Study NCT03967015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Administered Malnutrition Monitoring System (MAMMS)
Description: Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
Study NCT04689295 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise programme 2
Description: Traditional scoliosis exercises
Study NCT03913884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor
Description: CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
Study NCT03913884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Concentrated growth factor Group
Description: To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
Study NCT03713632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300mg every 2 or every 4 weeks
Study NCT02629666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERS and/or Self-management Strategies
Study NCT01545050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
Study NCT02540291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7046
Description: E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
Study NCT01420419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lanolin
Description: Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
Study NCT01420419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard (usual) in-hospital and community postpartum care
Description: Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
Study NCT04293367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery).
Study NCT00126984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination
Study NCT02765425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES
Description: Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
Study NCT04303780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: 21 day cycles
Study NCT00126984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa/Hib containing vaccine
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
Study NCT00126984 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa/Hib containing vaccine
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
Study NCT00126984 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age